- Home
- AORT vs NRIX Comparison
AORT vs NRIX Comparison
Compare AORT & NRIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AORT
- NRIX
- Stock Information
- Founded
- AORT 1984
- NRIX 2009
- Country
- AORT United States
- NRIX United States
- Employees
- AORT N/A
- NRIX N/A
- Industry
- AORT Medical/Dental Instruments
- NRIX Biotechnology: Pharmaceutical Preparations
- Sector
- AORT Health Care
- NRIX Health Care
- Exchange
- AORT Nasdaq
- NRIX Nasdaq
- Market Cap
- AORT 1.2B
- NRIX 1.4B
- IPO Year
- AORT 1993
- NRIX 2020
- Fundamental
- Price
- AORT $30.73
- NRIX $19.14
- Analyst Decision
- AORT Strong Buy
- NRIX Strong Buy
- Analyst Count
- AORT 5
- NRIX 17
- Target Price
- AORT $31.80
- NRIX $30.29
- AVG Volume (30 Days)
- AORT 343.4K
- NRIX 832.5K
- Earning Date
- AORT 02-13-2025
- NRIX 02-13-2025
- Dividend Yield
- AORT N/A
- NRIX N/A
- EPS Growth
- AORT N/A
- NRIX N/A
- EPS
- AORT N/A
- NRIX N/A
- Revenue
- AORT $384,899,000.00
- NRIX $56,424,000.00
- Revenue This Year
- AORT $12.95
- NRIX N/A
- Revenue Next Year
- AORT $9.76
- NRIX $3.79
- P/E Ratio
- AORT N/A
- NRIX N/A
- Revenue Growth
- AORT 13.29
- NRIX N/A
- 52 Week Low
- AORT $16.48
- NRIX $7.65
- 52 Week High
- AORT $32.33
- NRIX $29.56
- Technical
- Relative Strength Index (RSI)
- AORT 61.77
- NRIX 45.09
- Support Level
- AORT $28.83
- NRIX $17.50
- Resistance Level
- AORT $32.33
- NRIX $20.50
- Average True Range (ATR)
- AORT 0.97
- NRIX 1.12
- MACD
- AORT 0.21
- NRIX 0.16
- Stochastic Oscillator
- AORT 66.84
- NRIX 54.67
About AORT Artivion Inc.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others.
About NRIX Nurix Therapeutics Inc. Common stock
Nurix Therapeutics Inc is a biopharmaceutical company focused on the discovery, development and commercialization of oral, small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and immune disorders. The company's pipeline comprises targeted protein degraders of Brutons tyrosine kinase, or BTK, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene-B, or CBL-B, an E3 ligase that regulates T cell activation. Its drug candidate from protein degradation portfolio, NX-2127, is an orally available BTK degrader for the treatment of relapsed or refractory B-cell malignancies. Its drug candidate from E3 ligase inhibitor portfolio, NX-1607, is an orally available CBL-B inhibitor for immuno-oncology indications.